ACE-031 vs PEG-MGF
A side-by-side research comparison of ACE-031 and PEG-MGF across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | ACE-031 | PEG-MGF |
|---|---|---|
| Full name | ACE-031 (Soluble ActRIIB-Fc Fusion) | PEGylated Mechano Growth Factor |
| Category | Muscle Growth | Muscle Growth |
| Status | Investigational | Research compound |
| Mechanism | Decoy receptor sequestering TGF-B ligands (myostatin, activin, GDF-11) in bloodstream, preventing cell-surface ActRIIB binding and removing multiple anabolic brakes. | PEGylation protects MGF from rapid degradation, extending half-life from minutes to hours. Activates satellite cells systemically for whole-body muscle recovery. |
| Molecular weight | ~90,000 Da | ~5000 Da (with PEG) |
| Half-life | 10-14 days | ~30 minutes to several hours (vs 5-7 min native) |
| Bioavailability | High (SubQ) | ~85% subcutaneous |
| Typical dose | 0.3-3 mg/kg | 100-200 mcg |
| Frequency | Every 2-4 weeks | 2-3x per week |
| Route | Subcutaneous | Subcutaneous injection |
ACE-031 reported benefits
- Multi-ligand pathway inhibition
- Lean mass increase
- Bone density increase
- Infrequent dosing
- Functional strength improvement
PEG-MGF reported benefits
- Extended half-life vs native MGF
- Systemic satellite cell activation
- Whole-body recovery
- Less frequent dosing
Related comparisons
Research and educational reference only. Not medical advice.